RT Journal Article
SR Electronic
T1 Pediatric and Adult Patients with ME/CFS following COVID-19: A Structured Approach to Diagnosis Using the Munich Berlin Symptom Questionnaire (MBSQ)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.23.23293081
DO 10.1101/2023.08.23.23293081
A1 Peo, Laura C.
A1 Wiehler, Katharina
A1 Paulick, Johannes
A1 Gerrer, Katrin
A1 Leone, Ariane
A1 Viereck, Anja
A1 Haegele, Matthias
A1 Stojanov, Silvia
A1 Warlitz, Cordula
A1 Augustin, Silvia
A1 Alberer, Martin
A1 Hattesohl, Daniel B. R.
A1 Froehlich, Laura
A1 Scheibenbogen, Carmen
A1 Mihatsch, Lorenz
A1 Pricoco, Rafael
A1 Behrends, Uta
YR 2023
UL http://medrxiv.org/content/early/2023/08/24/2023.08.23.23293081.abstract
AB Purpose A subset of patients with post-COVID-19 condition (PCC) fulfill the clinical criteria of myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). To establish the diagnosis of ME/CFS for clinical and research purposes, comprehensive scores have to be evaluated.Methods We developed the Munich Berlin Symptom Questionnaires (MBSQs) and supplementary scoring sheets (SSSs) to allow for a rapid evaluation of common ME/CFS case definitions. The MBSQs were applied to young patients with chronic fatigue and post-exertional malaise (PEM) who presented to the MRI Chronic Fatigue Center for Young People (MCFC). Trials were retrospectively registered (NCT05778006, NCT05638724).Results Using the MBSQs and SSSs, we report on ten patients aged 11 to 25 years diagnosed with ME/CFS after asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19. Results from their MBSQs and from well-established patient-reported outcome measures indicated severe impairments of daily activities and health-related quality of life.Conclusions ME/CFS can follow SARS-CoV-2 infection in patients younger than 18 years, rendering structured diagnostic approaches most relevant for pediatric PCC clinics. The MBSQs and SSSs represent novel diagnostic tools that can facilitate the diagnosis of ME/CFS in children, adolescents, and adults with PCC and other post-viral syndromes.What is known ME/CFS is a frequent debilitating illness. For diagnosis, an extensive differential diagnostic workup is required and the evaluation of clinical ME/CFS criteria. ME/CFS following COVID-19 has been reported in adults but not in pediatric patients younger than 19 years of age.What is new We present novel questionnairs (MBSQs), as tools to assess common ME/CFS case definitions in pediatric and adult patients with post-COVID-19 condition and beyond. We report on ten patients aged 11 to 25 years diagnosed with ME/CFS following asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19.Competing Interest StatementU.B. received research grants from the Federal Ministry of Education and Research (BMBF), the Federal Ministry of Health (BMG), the Bavarian Ministry of Health and Care (StMGP), the Bavarian Ministry of Science and Arts (StMWK), the German Center for Infection Research (DZIF), the People for Children (Menschen fuer Kinder) foundation, the Weidenhammer-Zoebele foundation, the Lost-Voices foundation, and the ME/CFS research foundation. C.S. was consulting Roche, Celltrend, and Bayer; she received support for clinical trials by Bayer, Fresenius, and Miltenyi, honoraria for lectures by Fresenius, AstraZeneca, BMS, Roche, Bayer, and Novartis, and research grants from the German Research Association (DFG), the BMBF, the BMG, the Weidenhammer-Zoebele foundation, the Lost-Voices foundation, and the ME/CFS research foundation. The other authors declare no conflict of interest. Funding StatementThis work was supported by the Bavarian Ministry of Health and Care, the Weidenhammer-Zoebele, and the Lost-Voices foundations.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of the Technical University of Munich gave ethical approval for this work (116/21, 511/21).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesANAantinuclear antibodiesCCCCanadian consensus criteriaCDCCenters of Disease Control and PreventionCDW-Rclinical diagnostic worksheet of P.C. Rowe et al. (2017)CFCCharité Fatigue CenterCOVID-19coronavirus disease 2019CRPC-reactive proteinDSQDePaul symptom questionnaireEBVEpstein-Barr virusECGelectrocardiographyEEGelectroencephalographyEUROMENEEuropean Network on ME/CFSGETgraded exercise therapyHRheart rateHRQoLhealth-related quality of lifeIOMInstitute of MedicineKBVGerman National Association of Statutory Health Insurance PhysiciansMBSQMunich Berlin Symptom QuestionnaireMCFCMRI Chronic Fatigue Center for Young PeopleME/CFSmyalgic encephalomyelitis / chronic fatigue syndromeMRITUM university hospital (Klinikum rechts der Isar)MRTmagnetic resonance tomographyNICENational Institute for Health and Care ExcellenceOHorthosthatic hypotensionOIorthosthatic intolerancePASCpost-acute sequelae of COVID-19PCCpost-COVID-19 conditionPCD-Jpediatric case definition by L.A. Jason et al. (2006)PEMpost-exertional malaisePFTpulmonary function testingPoTSpostural tachcardia syndromePROMpatient-reported outcome measureRT-PCRreverse transcriptase - polymerase chain reactionSARS-CoV-2severe acute respiratory coronavirus type 2SEIDsystemic exertion intolerance disease criteriaSF-36Short Form 36SSSSupplementary Scoring SheetUCGultrasound cardiographyWHOWorld Health Organisation